Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
7 evidence topics · 4 sources
Absorption and terminal half-life of single-agent darovasertib under fasting conditions
“During the dose escalation part of the study, following oral doses of 100–1000 mg QD and 200–400 mg BID, total plasma concentration profiles of LXS196 showed rapid absorption in fasting conditions with a Tmax of ~1 h after dose (median Tmax ranging from 0.483–2.00 h) and consistent terminal T1/2 across different doses (~11 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean terminal half-life (T1/2) was consistent across tested dose groups ranging from 8.49–13.8 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Accumulation, variability, and dose proportionality of single-agent darovasertib
“Minimal or reduced accumulation was observed with repeated administration (mean Racc ranged from 0.718 to 1.27-fold).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PK variability was moderate, as illustrated by the between-patient variability (CV%) for Cmax and for AUC0–t.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increase in exposure (AUC0–t and Cmax) on C1D1 and D15 was under-proportional to the increase in dose with both QD and BID schedules.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic sampling and parameters in the first-in-human study
“In the dose escalation part of the study, PK samples were collected at various pre- and post-dose time points on C1D1, D2, D3, D15 and D16.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PK parameters included area under the curve (AUC0–12h), maximum concentration (Cmax) and time to Cmax (Tmax) on C1D1 and C1D15, and additionally, the accumulation ratio (Racc) of AUC0–t on C1D15 compared to that on C1D1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absorption and tolerability in preclinical species
Pharmacokinetic endpoints in the OptimUM-02 EU trial record
Darovasertib pharmacokinetics in combination with crizotinib
No evidence found.